Bo Xu1, Huihui Cheng2, Kunhong Li3,4, Yukai Lv5, Xianshang Zeng6, Tao Liu7,8, Weiguang Yu6, Wenbo Guo9. 1. Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China. 2. Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, China. 3. Department of Anesthesiology, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 3, Gutian Road, Qiaokou District, Wuhan, 430000, China. 4. Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 3, Gutian Road, Qiaokou District, Wuhan, 430000, China. 5. Department of Pediatrics, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China. 6. Department of Orthopaedics, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China. 7. Department of Intensive Care Unit, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 3, Gutian Road, Qiaokou District, Wuhan, 430000, China. liutao050124@163.com. 8. Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 3, Gutian Road, Qiaokou District, Wuhan, 430000, China. liutao050124@163.com. 9. Department of Invasive Technology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China.
Abstract
PURPOSE: The aim of this retrospective review was to compare the efficacy and safety of the atezolizumab plus carboplatin and nab-paclitaxel regimen versus the carboplatin and nab-paclitaxel regimen as front-line management for treatment-naïve, metastatic nonsquamous programmed death-ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) in a selected population. METHODS: Consecutive patients with untreated, metastatic nonsquamous PD-L1-positive NSCLC who initially received the atezolizumab plus carboplatin and nab-paclitaxel (ACN) regimen or carboplatin and nab-paclitaxel (CN) regimen were retrospectively identified in two medical institutions from 2017 to 2020. The co-primary end points were overall survival (OS) and progression-free survival (PFS); secondary end point was the rate of key adverse events (AEs). RESULTS: In sum, 171 patients were retrospectively analysed, 47 of whom were excluded according to the criteria used in this study, leaving 124 patients (ACN: n = 60, median age 64 years [range 46-75]; CN: n = 64, 63 years [47-72]). The median duration of follow-up was 27 months [range 1-37]. At the final follow-up, the median OS was 19.9 months (95% confidence interval [CI], 16.3-22.5) in the ACN group vs. 14.8 months (95% CI 12.5-17.2) in the CN group (hazard ratio [HR] 0.51, 95% CI 0.33-0.77; p = 0.001). A marked distinction in the median PFS was seen (8.5 months [95% CI 6.7-9.4] in the ACN group vs. in the CN group [5.1 months [95% CI 3.6-6.8; HR 0.60; 95% CI 0.38-0.95; p = 0.005]). The rates of the key AEs (neutropenia and anaemia) were greater in the ACN group than in the CN group (all p < 0.05), but these AEs were manageable. CONCLUSION: Among selected populations of individuals with treatment-naïve, metastatic nonsquamous PD-L1-positive NSCLC, atezolizumab combined with carboplatin and nab-paclitaxel chemotherapy might have encouraging anticancer activity, with a tolerable safety profile.
PURPOSE: The aim of this retrospective review was to compare the efficacy and safety of the atezolizumab plus carboplatin and nab-paclitaxel regimen versus the carboplatin and nab-paclitaxel regimen as front-line management for treatment-naïve, metastatic nonsquamous programmed death-ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) in a selected population. METHODS: Consecutive patients with untreated, metastatic nonsquamous PD-L1-positive NSCLC who initially received the atezolizumab plus carboplatin and nab-paclitaxel (ACN) regimen or carboplatin and nab-paclitaxel (CN) regimen were retrospectively identified in two medical institutions from 2017 to 2020. The co-primary end points were overall survival (OS) and progression-free survival (PFS); secondary end point was the rate of key adverse events (AEs). RESULTS: In sum, 171 patients were retrospectively analysed, 47 of whom were excluded according to the criteria used in this study, leaving 124 patients (ACN: n = 60, median age 64 years [range 46-75]; CN: n = 64, 63 years [47-72]). The median duration of follow-up was 27 months [range 1-37]. At the final follow-up, the median OS was 19.9 months (95% confidence interval [CI], 16.3-22.5) in the ACN group vs. 14.8 months (95% CI 12.5-17.2) in the CN group (hazard ratio [HR] 0.51, 95% CI 0.33-0.77; p = 0.001). A marked distinction in the median PFS was seen (8.5 months [95% CI 6.7-9.4] in the ACN group vs. in the CN group [5.1 months [95% CI 3.6-6.8; HR 0.60; 95% CI 0.38-0.95; p = 0.005]). The rates of the key AEs (neutropenia and anaemia) were greater in the ACN group than in the CN group (all p < 0.05), but these AEs were manageable. CONCLUSION: Among selected populations of individuals with treatment-naïve, metastatic nonsquamous PD-L1-positive NSCLC, atezolizumab combined with carboplatin and nab-paclitaxel chemotherapy might have encouraging anticancer activity, with a tolerable safety profile.
Authors: Scott J Antonia; Hossein Borghaei; Suresh S Ramalingam; Leora Horn; Javier De Castro Carpeño; Adam Pluzanski; Marco A Burgio; Marina Garassino; Laura Q M Chow; Scott Gettinger; Lucio Crinò; David Planchard; Charles Butts; Alexander Drilon; Joanna Wojcik-Tomaszewska; Gregory A Otterson; Shruti Agrawal; Ang Li; John R Penrod; Julie Brahmer Journal: Lancet Oncol Date: 2019-08-14 Impact factor: 41.316
Authors: Stephen V Liu; D Ross Camidge; Scott N Gettinger; Giuseppe Giaccone; Rebecca S Heist; F Stephen Hodi; Neal E Ready; Wei Zhang; Jeffrey Wallin; Roel Funke; Daniel Waterkamp; Paul Foster; Koho Iizuka; John Powderly Journal: Eur J Cancer Date: 2018-07-24 Impact factor: 9.162
Authors: Solange Peters; Scott Gettinger; Melissa L Johnson; Pasi A Jänne; Marina C Garassino; Daniel Christoph; Chee Keong Toh; Naiyer A Rizvi; Jamie E Chaft; Enric Carcereny Costa; Jyoti D Patel; Laura Q M Chow; Marianna Koczywas; Cheryl Ho; Martin Früh; Michel van den Heuvel; Jeffrey Rothenstein; Martin Reck; Luis Paz-Ares; Frances A Shepherd; Takayasu Kurata; Zhengrong Li; Jiaheng Qiu; Marcin Kowanetz; Simonetta Mocci; Geetha Shankar; Alan Sandler; Enriqueta Felip Journal: J Clin Oncol Date: 2017-06-13 Impact factor: 44.544
Authors: Louis Fehrenbacher; Alexander Spira; Marcus Ballinger; Marcin Kowanetz; Johan Vansteenkiste; Julien Mazieres; Keunchil Park; David Smith; Angel Artal-Cortes; Conrad Lewanski; Fadi Braiteh; Daniel Waterkamp; Pei He; Wei Zou; Daniel S Chen; Jing Yi; Alan Sandler; Achim Rittmeyer Journal: Lancet Date: 2016-03-10 Impact factor: 79.321
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: Martin Reck; Geetha Shankar; Anthony Lee; Shelley Coleman; Mark McCleland; Vassiliki A Papadimitrakopoulou; Mark A Socinski; Alan Sandler Journal: Expert Rev Respir Med Date: 2019-12-12 Impact factor: 3.772